cyclophosphamide + docetaxel + pirarubicin

This is a combination chemotherapy regimen consisting of three cytotoxic agents: - Cyclophosphamide, an alkylating agent that crosslinks DNA, leading to cell death. - Docetaxel, a taxane that stabilizes microtubules and inhibits their depolymerization, thereby blocking cell division. - Pirarubicin, an anthracycline antibiotic structurally related to doxorubicin and epirubicin; it intercalates into DNA and inhibits topoisomerase II activity, resulting in inhibition of DNA replication and repair. This combination is designed for the treatment of various cancers—most notably breast cancer—leveraging the synergistic effects of these agents. While regimens with similar drugs (such as docetaxel + cyclophosphamide or docetaxel + epirubicin + cyclophosphamide) are well established in breast cancer therapy[1][2][3][4][5], specific published data on the use of pirarubicin instead of other anthracyclines in this exact triplet are limited. The mechanism involves multiple pathways targeting rapidly dividing tumor cells.